Welcome to our dedicated page for BECTON DICKINSON & CO SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BECTON DICKINSON & CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BECTON DICKINSON & CO's regulatory disclosures and financial reporting.
Becton Dickinson & Co. director reports no beneficial ownership
A director of Becton Dickinson & Co. (BDX) filed an initial statement of beneficial ownership of securities. As of the event date of 12/01/2025, the reporting person states that they beneficially own no non-derivative securities of the company and list no derivative securities such as options or warrants. The filing is made on behalf of the director under a power of attorney, which is referenced as an attached exhibit.
Becton, Dickinson and Company insider plans small Rule 144 sale. A person identified as Michael Feld has filed a notice of proposed sale of 75 shares of Becton, Dickinson common stock, to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 12/01/2025. The 75 shares come from restricted stock units acquired on 08/20/2025. The filing notes that Becton, Dickinson had 285,418,551 common shares outstanding when this notice was prepared, which serves as a baseline ownership figure. The notice also lists prior Rule 10b5-1 sales during the past three months of 57 shares for gross proceeds of $10,602.57 and 58 shares for gross proceeds of $10,499.74. The signer represents that they are not aware of undisclosed material adverse information about the company.
Becton, Dickinson and Company filed an amended current report to update information about two newly elected directors. The amendment adds details on the compensation arrangements for Robert L. Huffines and Jacqueline Wright, who joined the Board of Directors effective December 1, 2025. Each will receive restricted stock units valued at $33,575, representing a prorated equity grant covering the period from their effective election date through BD’s 2026 Annual Meeting of Shareholders. All other information about their elections and the Board disclosed previously remains the same.
Becton, Dickinson and Company executive Pavan Mocherla, EVP & President, Greater Asia, reported equity awards in company stock. On 11/26/2025, he acquired 2,208 shares of common stock, described as restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan, at a reporting price of $0 per share. After this grant, he beneficially owned 5,055 shares directly.
On the same date, he also acquired 708 shares of common stock at a reporting price of $0 per share, identified as shares received upon vesting of performance-based equity awards, bringing his directly owned total to 5,763 shares. The filing is made on Form 4, which discloses changes in the insider’s beneficial ownership of Becton Dickinson & Co (BDX) common stock.
Becton, Dickinson and Company executive David Shan reported equity transactions in BDX stock. On 11/26/2025, he received 3,504 restricted stock units under the company’s 2004 Employee and Director Equity-Based Compensation Plan and 1,025 shares from vesting of performance-based equity awards, both at a stated price of $0 per share as these are compensation-related grants.
On the same date, 134 shares of common stock were withheld to cover taxes related to these vestings. After these transactions, Shan directly beneficially owned 8,970 shares of Becton Dickinson common stock. He is listed as an Executive Vice President and Chief ISC Officer, and the filing is made for one reporting person.
Becton, Dickinson and Company executive equity activity: Executive Vice President and Chief People Officer Shana Carol Neal reported equity transactions in Becton Dickinson & Co common stock. On 11/26/2025, she acquired 6,727 shares of common stock as restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan, and 3,525 shares received upon vesting of performance-based equity awards, both at a stated price of $0 per share. The filing also reports 2,454 shares withheld to cover taxes related to the vesting of these performance units and previously reported restricted stock units. After these transactions, she directly beneficially owned 21,326 shares of Becton Dickinson common stock.
Becton, Dickinson and Company executive Roland Goette, EVP and President, EMEA, reported routine equity compensation activity. On 11/26/2025, he acquired 1,906 shares of common stock from restricted stock units granted under the company’s 2004 equity-based compensation plan and 1,237 shares received upon vesting of performance-based equity awards, both at a price of $0 as these are compensation grants.
On the same date, 138 shares were disposed of at a stated price of $0 to cover withholding taxes related to the vesting events. After these transactions, Goette directly owned 17,222 shares of common stock and indirectly held 1,559 shares through the Global Share Investment Program as of November 24, 2025.
Becton, Dickinson and Company executive equity transaction: On 11/26/2025, EVP & President, Medical Essential & BioPharm, Michael David Garrison reported multiple equity-related transactions in Becton Dickinson & Co common stock.
He acquired 7,568 shares as restricted stock units awarded under the company’s 2004 Employee and Director Equity-Based Compensation Plan and 3,048 shares received upon vesting of performance-based equity awards, both at a price of $0 per share. In connection with these vestings, 1,769 shares were withheld to cover withholding taxes.
Following these transactions, he beneficially owned 13,734 shares of Becton Dickinson & Co common stock in direct ownership.
Becton Dickinson & Co executive reports equity award activity. Michael Feld, EVP, CRO & President, Life Sciences, reported transactions in Becton Dickinson & Co common stock on 11/26/2025. He acquired 8,829 shares at a price of $0, reflecting the vesting of restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
On the same date, 419 shares were disposed of at $0 to cover withholding taxes related to the vesting of previously reported restricted stock units. After these transactions, Feld directly beneficially owned 16,655 shares of Becton Dickinson & Co common stock.
Becton Dickinson & Co. executive vice president and chief financial officer Christopher DelOrefice reported routine equity award activity. On 11/26/2025, he acquired 6,006 shares of common stock at $0 per share, representing shares received upon vesting of performance-based equity awards. On the same date, 4,245 shares were disposed of at $0 per share, reflecting shares withheld to cover tax obligations tied to this vesting and previously granted restricted stock units. After these transactions, DelOrefice directly beneficially owned 22,982 shares of Becton Dickinson common stock.